Oncternal Intangible Assets vs Accounts Payable Analysis

ONCT Stock

USD 1.14 0.02 1.72%

Oncternal Therapeutics financial indicator trend analysis is much more than just breaking down Oncternal Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncternal Therapeutics is a good investment. Please check the relationship between Oncternal Therapeutics Intangible Assets and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.

Intangible Assets vs Accounts Payable

Intangible Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncternal Therapeutics Intangible Assets account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Oncternal Therapeutics' Intangible Assets and Accounts Payable is -0.32. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Oncternal Therapeutics, assuming nothing else is changed. The correlation between historical values of Oncternal Therapeutics' Intangible Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Oncternal Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Intangible Assets i.e., Oncternal Therapeutics' Intangible Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.32

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Accounts Payable

An accounting item on the balance sheet that represents Oncternal Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Oncternal Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Oncternal Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncternal Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncternal Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.At this time, Oncternal Therapeutics' Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 11.81 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3.1 M in 2024.

	2010	2023	2024 (projected)
Reconciled Depreciation	47K	41.4K	37.2K
Discontinued Operations	13.9M	12.5M	11.1M

Reconciled Depreciation Discontinued Operations

Oncternal Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Non Currrent Assets Other	Inventory	Short Long Term Debt Total	Current Deferred Revenue	Intangible Assets
Total Assets		-0.47	-0.88	0.25	0.88	-0.04	1.0	0.13	-0.09	-0.02	1.0	-0.03	-0.02	-0.12	0.24	0.33	0.18	-0.38	0.37	-0.12	0.16	0.07	-0.01	-0.36	-0.46	-0.33
Total Stockholder Equity	-0.47		0.49	-0.5	-0.49	-0.29	-0.47	-0.16	0.46	0.09	-0.47	0.12	0.08	0.35	-0.28	-0.3	-0.02	-0.04	-0.45	0.35	-0.09	-0.58	-0.03	0.28	0.16	0.15
Net Debt	-0.88	0.49		-0.29	-1.0	0.17	-0.89	0.14	0.18	0.16	-0.88	0.19	0.14	0.02	-0.17	-0.34	-0.02	0.22	-0.23	0.02	-0.14	-0.18	0.19	0.61	0.39	0.17
Retained Earnings	0.25	-0.5	-0.29		0.3	0.71	0.25	-0.28	-0.98	-0.39	0.24	-0.4	-0.4	0.29	-0.18	0.68	-0.29	0.47	-0.25	0.29	-0.38	0.86	0.46	-0.22	-0.53	0.34
Cash	0.88	-0.49	-1.0	0.3		-0.17	0.89	-0.14	-0.18	-0.16	0.88	-0.19	-0.14	-0.03	0.17	0.34	0.02	-0.22	0.23	-0.03	0.14	0.18	-0.19	-0.61	-0.39	-0.17
Other Assets	-0.04	-0.29	0.17	0.71	-0.17		-0.05	0.19	-0.69	-0.4	-0.05	-0.37	-0.42	0.23	0.11	0.38	-0.35	0.54	-0.04	0.23	-0.55	0.7	0.69	0.18	-0.43	0.36
Cash And Short Term Investments	1.0	-0.47	-0.89	0.25	0.89	-0.05		0.1	-0.1	-0.02	1.0	-0.03	-0.01	-0.11	0.23	0.33	0.18	-0.36	0.34	-0.11	0.17	0.08	-0.03	-0.38	-0.46	-0.32
Common Stock Shares Outstanding	0.13	-0.16	0.14	-0.28	-0.14	0.19	0.1		0.33	-0.02	0.13	-0.02	-0.04	-0.53	0.63	-0.44	0.03	-0.43	0.64	-0.53	-0.2	-0.32	0.04	0.59	0.11	-0.56
Other Stockholder Equity	-0.09	0.46	0.18	-0.98	-0.18	-0.69	-0.1	0.33		0.36	-0.08	0.37	0.36	-0.31	0.25	-0.65	0.3	-0.54	0.32	-0.31	0.37	-0.88	-0.44	0.2	0.45	-0.41
Total Liab	-0.02	0.09	0.16	-0.39	-0.16	-0.4	-0.02	-0.02	0.36		-0.02	0.99	1.0	-0.32	-0.39	-0.3	0.89	-0.26	0.07	-0.32	0.87	-0.44	-0.31	0.17	0.35	-0.22
Total Current Assets	1.0	-0.47	-0.88	0.24	0.88	-0.05	1.0	0.13	-0.08	-0.02		-0.03	-0.01	-0.12	0.24	0.32	0.18	-0.38	0.37	-0.12	0.16	0.07	-0.02	-0.36	-0.45	-0.33
Other Current Liab	-0.03	0.12	0.19	-0.4	-0.19	-0.37	-0.03	-0.02	0.37	0.99	-0.03		0.99	-0.28	-0.43	-0.31	0.9	-0.22	0.04	-0.28	0.87	-0.45	-0.26	0.18	0.32	-0.17
Total Current Liabilities	-0.02	0.08	0.14	-0.4	-0.14	-0.42	-0.01	-0.04	0.36	1.0	-0.01	0.99		-0.33	-0.38	-0.3	0.88	-0.26	0.09	-0.33	0.88	-0.44	-0.34	0.14	0.37	-0.21
Property Plant And Equipment Net	-0.12	0.35	0.02	0.29	-0.03	0.23	-0.11	-0.53	-0.31	-0.32	-0.12	-0.28	-0.33		-0.25	0.62	-0.23	0.61	-0.54	1.0	-0.2	0.38	0.65	-0.5	-0.55	0.83
Accounts Payable	0.24	-0.28	-0.17	-0.18	0.17	0.11	0.23	0.63	0.25	-0.39	0.24	-0.43	-0.38	-0.25		-0.04	-0.4	-0.25	0.57	-0.25	-0.34	0.02	0.01	-0.03	-0.07	-0.32
Non Current Assets Total	0.33	-0.3	-0.34	0.68	0.34	0.38	0.33	-0.44	-0.65	-0.3	0.32	-0.31	-0.3	0.62	-0.04		-0.13	0.29	-0.25	0.62	-0.12	0.73	0.63	-0.57	-0.7	0.4
Common Stock Total Equity	0.18	-0.02	-0.02	-0.29	0.02	-0.35	0.18	0.03	0.3	0.89	0.18	0.9	0.88	-0.23	-0.4	-0.13		-0.33	0.04	-0.23	0.9	-0.38	-0.14	0.11	0.09	-0.25
Non Current Liabilities Total	-0.38	-0.04	0.22	0.47	-0.22	0.54	-0.36	-0.43	-0.54	-0.26	-0.38	-0.22	-0.26	0.61	-0.25	0.29	-0.33		-0.42	0.61	-0.26	0.65	0.45	-0.34	-0.27	0.93
Other Current Assets	0.37	-0.45	-0.23	-0.25	0.23	-0.04	0.34	0.64	0.32	0.07	0.37	0.04	0.09	-0.54	0.57	-0.25	0.04	-0.42		-0.54	0.08	-0.17	-0.11	0.08	0.2	-0.51
Property Plant And Equipment Gross	-0.12	0.35	0.02	0.29	-0.03	0.23	-0.11	-0.53	-0.31	-0.32	-0.12	-0.28	-0.33	1.0	-0.25	0.62	-0.23	0.61	-0.54		-0.2	0.38	0.65	-0.5	-0.55	0.83
Common Stock	0.16	-0.09	-0.14	-0.38	0.14	-0.55	0.17	-0.2	0.37	0.87	0.16	0.87	0.88	-0.2	-0.34	-0.12	0.9	-0.26	0.08	-0.2		-0.33	-0.33	-0.2	0.22	-0.15
Non Currrent Assets Other	0.07	-0.58	-0.18	0.86	0.18	0.7	0.08	-0.32	-0.88	-0.44	0.07	-0.45	-0.44	0.38	0.02	0.73	-0.38	0.65	-0.17	0.38	-0.33		0.52	-0.43	-0.53	0.52
Inventory	-0.01	-0.03	0.19	0.46	-0.19	0.69	-0.03	0.04	-0.44	-0.31	-0.02	-0.26	-0.34	0.65	0.01	0.63	-0.14	0.45	-0.11	0.65	-0.33	0.52		-0.03	-0.55	0.53
Short Long Term Debt Total	-0.36	0.28	0.61	-0.22	-0.61	0.18	-0.38	0.59	0.2	0.17	-0.36	0.18	0.14	-0.5	-0.03	-0.57	0.11	-0.34	0.08	-0.5	-0.2	-0.43	-0.03		0.45	-0.47
Current Deferred Revenue	-0.46	0.16	0.39	-0.53	-0.39	-0.43	-0.46	0.11	0.45	0.35	-0.45	0.32	0.37	-0.55	-0.07	-0.7	0.09	-0.27	0.2	-0.55	0.22	-0.53	-0.55	0.45		-0.31
Intangible Assets	-0.33	0.15	0.17	0.34	-0.17	0.36	-0.32	-0.56	-0.41	-0.22	-0.33	-0.17	-0.21	0.83	-0.32	0.4	-0.25	0.93	-0.51	0.83	-0.15	0.52	0.53	-0.47	-0.31

Click cells to compare fundamentals

Oncternal Therapeutics Account Relationship Matchups

Oncternal Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	21.7M	118.8M	93.6M	68.7M	36.7M	61.3M
Total Stockholder Equity	14.3M	(82.8M)	(114.1M)	(158.3M)	30.1M	31.6M
Net Debt	(19.9M)	(116.7M)	(90.7M)	(37.1M)	(6.4M)	(6.7M)
Retained Earnings	(65.6M)	(82.8M)	(114.1M)	(158.3M)	(197.8M)	(207.7M)
Cash	20.1M	116.7M	90.8M	37.1M	6.7M	6.4M
Other Assets	767K	806K	657K	1.3M	1.1M	1.7M
Cash And Short Term Investments	20.1M	116.7M	90.8M	63.7M	34.3M	55.2M
Common Stock Shares Outstanding	516.4K	1.0M	2.5M	2.6M	2.9M	3.1M
Liabilities And Stockholders Equity	21.7M	(76.9M)	(108.7M)	68.7M	36.7M	31.8M
Other Stockholder Equity	79.9M	195.7M	202.2M	219.2M	227.8M	321.4M
Total Liab	7.4M	5.9M	5.5M	7.7M	6.7M	6.3M
Total Current Assets	20.8M	118.0M	92.9M	67.3M	36.1M	58.6M
Other Current Liab	2.7M	3.0M	3.4M	4.7M	3.9M	7.3M
Total Current Liabilities	7.3M	5.9M	5.5M	7.7M	5.2M	4.9M
Property Plant And Equipment Net	190K	40K	75K	87K	258K	245.1K
Accounts Payable	871K	1.1M	2.0M	2.9M	1.1M	1.6M
Non Current Assets Total	957K	806K	732K	1.4M	670K	636.5K
Common Stock Total Equity	24K	15K	49K	57K	65.6K	50.6K
Non Current Liabilities Total	91K	2.8M	2.0M	3.0M	1.5M	1.4M
Other Current Assets	736K	2.5M	1.5M	3.4M	1.2M	1.6M
Property Plant And Equipment Gross	190K	40K	75K	87K	258K	245.1K
Common Stock	24K	15K	49K	57K	3K	2.9K
Non Currrent Assets Other	767K	766K	657K	1.3M	412K	428.8K
Accumulated Other Comprehensive Income	(2.7M)	(2.6M)	0.0	9K	3K	3.2K
Net Tangible Assets	14.4M	113.0M	88.1M	61.0M	70.1M	35.9M
Retained Earnings Total Equity	(600.1M)	(65.6M)	(82.8M)	(158.3M)	(182.0M)	(191.1M)
Capital Surpluse	626.1M	79.9M	195.7M	219.2M	197.3M	340.7M
Property Plant Equipment	190K	40K	75K	87K	78.3K	152.8K
Net Invested Capital	14.3M	113.0M	88.1M	61.0M	30.1M	58.3M
Net Working Capital	13.4M	112.1M	87.4M	59.6M	30.9M	57.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Oncternal Stock Analysis

When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC